IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

An Overview On Of Fluvoxamine Maleate As An Antidepressant

Riya Lodha*, Dr. Kamal Singh Rathore, Vyankatesh Rajesh Panchariya

Department of Pharmaceutics

Bhupal Nobles' College of Pharmacy, Udaipur (313001), Rajasthan, India

ABSTRACT

As a selective serotonin reuptake inhibitor (SSRI), fluvoxamine has shown promise in large-scale, double-blind, randomized, controlled trials including people with panic disorder, obsessive-compulsive disorder (OCD), and social anxiety disorder (SAD). Furthermore, patients with a variety of obsessive-compulsive spectrum disorders, such as binge eating disorder, bulimia nervosa, pathological gambling, and body dysmorphic disorder, as well as those with post-traumatic stress disorder, have shown benefits. Fluvoxamine was the first SSRI to be licensed for the treatment of OCD in children and adolescents, and numerous well-controlled trials have confirmed its efficacy in treating OCD, SAD, and other anxiety disorders. Like other SSRIs, fluvoxamine is generally well tolerated; the most frequent adverse effect is nausea. It is not sedative or impairs cognitive function.

KEY WORDS

Selective serotonin reuptake inhibitors (SSRIs), anxiety disorders, panic disorder, obsessive-compulsive disorder (OCD), social anxiety disorder (SAD), sexual dysfunction, drowsiness, cognitive impairment, and fluoxamine maleate.

INTRODUCTION

Fluoxamine Maleate

The pharmaceutical substance fluoxamine maleate is widely used to treat a variety of mental illnesses and is mainly categorized as a selective serotonin reuptake inhibitor (SSRI). Fluoxamine was initially created to treat obsessive-compulsive disorder (OCD), but it has also shown promise in treating social anxiety disorder, panic disorder, and generalized anxiety disorder (GAD). It works by preventing serotonin from being reabsorbed in the brain, which increases the amount of serotonin—a neurotransmitter linked to mood regulation—that is available.

The pharmacokinetic characteristics of fluoxamine maleate are noteworthy. It has improved solubility as a maleate salt, which may increase the body's ability to absorb and use it. This is especially helpful for more efficiently reaching therapeutic levels, which enables the best possible treatment results. The medication is usually taken orally, with dosages customized to meet the patient's needs. Careful titration is frequently necessary to reduce adverse effects and maximize therapeutic benefits.

Although fluoxamine maleate has a generally good safety profile, there is a chance of negative side effects. In addition to central nervous system affects including sleepiness, sleeplessness, and sexual dysfunction, common side effects include gastrointestinal problems like nausea and diarrhea. Serotonin syndrome, particularly when taken with other serotonergic drugs, and the possibility of withdrawal symptoms if the medication is stopped suddenly are serious but uncommon adverse effects. Because of its well-established effectiveness and comparatively low side effect profile when compared to some other antidepressants, clinicians frequently take fluoxamine maleate into account when prescribing SSRIs. Its special qualities also make it a good choice for patients with particular anxiety disorders or those who might not react well to other SSRIs.

The use of fluoxamine in other settings, including its possible antiviral properties and its ability to treat post-traumatic stress disorder (PTSD), has also been investigated in recent years. As our knowledge of this drug grows, it remains a valuable weapon in the toolbox of mental health therapies, providing many people with crippling psychological disorders with hope and a better quality of life.

All things considered, fluoxamine maleate is a highly valued and well studied drug in the field of psychiatric treatment, serving as an example of the pharmacotherapy advancements made to treat complicated mental health conditions. As always, patients and healthcare professionals should work together to decide whether to utilize fluoxamine, taking into account each patient's unique situation and treatment objectives.

It is widely acknowledged that fluvoxamine was the first selective serotonin reuptake inhibitor (SSRI) to be used in clinical settings. Originally developed as an antidepressant (Wilde et al., 1993), for which it is licensed in many nations outside of the US, its primary application has changed to the treatment of anxiety disorders, including OCD. In the United States, it was the first drug approved for use in treating OCD in adults, and thereafter in children. Since fluvoxamine was the first SSRI to be authorized in Japan, numerous

studies have examined its efficacy in treating different anxiety disorders in recent years, including social anxiety disorder (SAD) and its Japanese equivalent, taijin kyofusho.

There isn't much recent research on fluvoxamine; the majority of previous reviews focused mostly on its use in treating depression. Even though fluvoxamine is unquestionably useful for depression, the drug is most commonly used to treat anxiety disorders, which indicates a lack of thorough assessments of its efficacy. The purpose of this study is to evaluate the data pertaining to fluvoxamine's effectiveness in treating post-traumatic stress disorder (PTSD), panic disorder, obsessive-compulsive spectrum disorders, OCD, and SAD. Benzodiazepines, tricyclic antidepressants, and neuroleptics were the conventional therapies for these disorders before the advent of SSRIs, and they frequently pose serious tolerability issues when compared to SSRIs. Compared to other SSRIs, fluvoxamine has probably been evaluated more thoroughly across a wider range of anxiety disorders, and the emergence of recent findings in this field necessitates further examination.

2D Structure



Fig: 1 [2D Structure of fluoxamine Maleate]

Molecular Formula

$C_{19}H_{25}F_3N_2O_6$

Antidepressant Drug

Fluoxamine maleate and other antidepressant drugs are essential for treating a number of mood disorders, including obsessive-compulsive disorder (OCD), anxiety disorders, and depression. The purpose of these drugs is to assist people with these diseases live better lives by reducing their symptoms. An extensive review of antidepressants is provided below, with particular attention to the traits, categories, and workings of medications such as fluoxamine maleate.

Overview of Antidepressants

Major depressive disorder (MDD) and other mood-related disorders are the main ailments treated by the varied class of drugs known as antidepressants. They function by altering the brain's neurotransmitter systems, especially those that deal with dopamine, serotonin, and norepinephrine. The creation of these drugs has greatly improved our knowledge of mental health and given millions of people access to efficient treatment alternatives.

Classification of Antidepressants

Antidepressants can be broadly categorized into several classes, each with distinct mechanisms of action:

1. **Selective Serotonin Reuptake Inhibitors (SSRIs)**:

Examples: Fluoxetine, fluoxamine, sertraline, escitalopram.
Mechanism: SSRIs primarily increase serotonin levels in the synaptic cleft by inhibiting its reuptake into the presynaptic neuron. This results in enhanced serotonergic neurotransmission, which is thought to improve mood and reduce anxiety.

2. **Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)**:

Examples: Venlafaxine, duloxetine.
Mechanism: SNRIs inhibit the reuptake of both serotonin and norepinephrine, which can be effective for both depressive and anxiety symptoms.

3. Tricyclic Antidepressants (TCAs):

Examples: Amitriptyline, nortriptyline, imipramine.
Mechanism: TCAs block the reuptake of norepinephrine and serotonin but also interact with other neurotransmitter systems, leading to a broader range of side effects.

4. **Monoamine Oxidase Inhibitors (MAOIs)**:

Examples: Phenelzine, tranylcypromine.
Mechanism: MAOIs inhibit the enzyme monoamine oxidase, which breaks down serotonin, norepinephrine, and dopamine, thus increasing their availability in the brain.

5. **Atypical Antidepressants**:

Examples: Bupropion, mirtazapine, trazodone.
Mechanism: These medications have varied mechanisms and often target multiple neurotransmitter systems, making them suitable for different patient profiles.

➢ **Limitations of Antidepressants-**



Pharmacology

One type of selective serotonin reuptake inhibitor (SSRI) antidepressant is fluvoxamine. It has little effect on the uptake mechanisms of dopamine and norepinephrine, but it successfully inhibits the reabsorption of serotonin. Moreover, fluvoxamine has a low affinity for a number of neurotransmitter receptors in addition to its interaction with σ1 receptors (Leonard 1992; Hyttel 1993). Interestingly, it has a higher affinity for σ1 receptors than other SSRIs, which may contribute to violent and psychotic behaviors (Narita *et al.* 1996).

Numerous animal studies, such as those involving ultrasonic vocalizations in rat pups, anticipatory anxiety tests in mice, and schedule-induced polydipsia in rats, have confirmed fluvoxamine's anxiolytic qualities (Njung'e and Handley, 1991; Olivier et al 1993; Woods *et al.*, 1993).

Pharmacokinetics

The principal pharmacokinetic characteristics of fluvoxamine are outlined in Table 1. Following oral administration, it is readily absorbed, and its bioavailability remains unaffected by food intake. Subsequently, it is widely distributed throughout the body, although it exhibits lower plasma protein binding compared to all other selective serotonin reuptake inhibitors (SSRIs), with the exception of citalopram. The liver extensively metabolizes fluvoxamine, with less than 4% of the administered dose being eliminated unchanged. None of the metabolites. produced exhibit psychotropic effects (Overmars et al 1983). The elimination half-life of fluvoxamine is approximately 15 hours after a single dose, whichcan increase by 30% to 50% with repeated dosing, making it appropriate for once-daily administration. The drug is primarily excreted through urine, and there is minimal transfer of fluoxamine into breast milk **(Piontek et al 2001).**

TABLE 1

Pharmacokinetic properties of fluvoxamine

Oral absorption	≥ 94%
C_{max}	31–87 mg/L
T_{max}	2–8 hours
Time to reach steady-state	≈ 10 days
Absolute bioavailability	≈ 50%
AUC	927 μg/L·hour
V_d	25 L/kg
Plasma protein binding	≈ 77%
$t_{½β}$	15 hours after a single dose
Route of metabolism	Hepatic oxidation
Route of excretion	Urine

Clinical studies and Clinical Efficacy

Social Anxiety Disorder (SAD)

Social Anxiety Disorder (SAD) ranks as the most prevalent anxiety disorder following specific phobia, with a lifetime prevalence rate of at least 10% **(Kessler et al., 1994; Weiller et al., 1996).** This disorder is marked by an intense fear of embarrassment in social or performance contexts. It can manifest in a generalized form, where individuals experience anxiety across a variety of situations such as public speaking, eating, writing in front of others, or engaging in group interactions. Alternatively, it may present in a nongeneralized form, where the anxiety is confined to one or two specific scenarios. The symptoms can be particularly debilitating in the generalized form, resulting in considerable disruption to educational, occupational, social, and familial aspects of life. As the onset typically occurs in adolescence or earlier, individuals may endure these challenges for many years, and the high likelihood of comorbidity with other psychiatric conditions further exacerbates their difficulties.

Efficacy in Depression

The effectiveness of fluoxamine in treating major depressive disorder (MDD) has been assessed in a number of trials. When compared to a placebo, fluoxamine dramatically lowers depression symptoms, according to randomized controlled trials (RCTs). Fluoxamine shows similar efficacy to other SSRIs, according to a meta-analysis of several trials, which makes it a good choice for treating depression.

Mechanism of Action

Serotonin levels in the synaptic cleft rise as a result of fluoxetine maleate's specific inhibition of serotonin reuptake in the brain. Serotonergic neurotransmission, which is thought to be essential for mood regulation and the reduction of depression symptoms, is improved by this method. Fluoxamine's overall therapeutic benefits may also be influenced by other neurotransmitter systems, including dopamine and norepinephrine.

Special Populations

Numerous populations, including those with treatment-resistant depression and associated anxiety disorders, have been the subject of fluoxetine research. Results indicate that fluoxamine may be useful in difficult situations, even in patients who have not responded to other antidepressants.

Safety Profile and Side Effects

While fluoxamine is generally well-tolerated, it is associated with several side effects. Common side effects include:

- **Gastrointestinal disturbances: Nausea, diarrhea, and dry mouth.**
- **Central nervous system effects: Drowsiness, insomnia, and anxiety.**
- **Sexual dysfunction: A common concern among patients, including decreased libido and delayed ejaculation.**

Rare but serious side effects, such as serotonin syndrome and increased risk of suicidal thoughts in younger populations, necessitate careful monitoring during treatment. Long-term use may lead to withdrawal symptoms upon discontinuation, making gradual tapering advisable.



Dosage and Administration

Depending on clinical response and tolerability, the initial dosage of fluoxamine for depression is usually adjusted from 50 to 100 mg daily. Taking into account variables including age, comorbid diseases, and concomitant drugs, healthcare providers should adjust dosage to meet the needs of each patient.

Perioperative care of the Patient with psychiatric Illness

Selective Serotonin Reuptake Inhibitors and Related Agents

The antidepressant drug class with the quickest rate of growth is SSRIs. They are used to treat eating disorders, anxiety, phobias, panic disorder, obsessive-compulsive disorder, depression, and premenstrual dysphoria. These currently consist of citalopram (Celexa), escitalopram (Lexapro), sertraline (Zoloft), fluvoxamine (Luvox), venlafaxine (Effexor), fluoxetine (Prozac), and paroxetine (Paxil). These medications are just as clinically effective (70%) as traditional antidepressants. They don't have any orthostatic hypotension or anticholinergic side effects like tricyclic antidepressants do. SSRIs tend to be stimulating rather than sedative, and they are rarely linked to conduction anomalies.

They could induce sleeplessness and nausea. The SSRIs mentioned above are arranged from most to least in terms of their ability to inhibit cytochrome P-450 2D6. A higher risk of bleeding results from interactions between warfarin and those with higher cytochrome P-450 activity. Additionally, these could raise phenytoin levels and, as a result, the toxicity risk. Venlafaxine, like a tricyclic drug, prevents serotonin and norepinephrine from being reabsorbed. Its negative effects, which include temporary nausea and vomiting, are more akin to those of other SSRIs. There is no impact on cardiac conduction. Additionally, venlafaxine may raise systolic blood pressure.

Nefazodone, mirtazapine (Remeron), buspirone (BuSpar), and bupropion (Wellbutrin) are further medications that have some effect on the serotonin pathway. Bupropion is used to treat depression characterized by excessive somnolence and psychomotor slowness. It primarily acts on the dopamine system. It's also used to help people quit smoking. Despite being a generally well-tolerated medication, bupropion carries a risk of seizures, especially in patients who have a history of seizures or epileptogenic focus, in patients who take large doses of the medicine (>450 mg/day), or in patients who are stopping alcohol or sedative-hypnotics. When taking bupropion with other dopaminergic medications, caution is advised. Buspirone affects α2-receptors, dopamine, and serotonin. The main condition for which it is used is generalized anxiety disorder.

Unlike the other SSRIs, this medication tends to produce a mild level of drowsiness. Nefazodone inhibits α1-receptors and acts on the serotonin and norepinephrine pathways. Depression is treated with it. It usually has little effect on sleep patterns, in contrast to the majority of other antidepressants. Nefazodone shares structural similarities with trazodone and can cause bradycardia, agitation, orthostasis, anticholinergic effects, and idiosyncratic liver damage. Digoxin, haloperidol, carbamazepine, and benzodiazepines are also elevated. Mirtazapine affects serotonin and norepinephrine levels via inhibiting α2-receptors. Compared to other antidepressants, it is less prone to have sexual adverse effects and is used to treat depression. It might make clonidine less effective.

Anxiety disorder: treatment consideration

Pharmacologic treatments, such as antidepressants like tricyclic antidepressants (clomipramine [Anafranil]) and SSRIs (fluvoxamine [Luvox]), must be the mainstay of treatment. When these drugs are stopped, relapse rates are substantial, indicating that long-term maintenance therapy is required to enhance symptom control and, eventually, the patient's quality of life [17]. Assessing the patient's degree of danger to oneself and others, as well as looking for indications of substance misuse, are examples of nonpharmacologic therapies that have been covered previously for different anxiety disorders. A key component of effective treatment planning is teaching the patient and their family about available treatments and symptoms to report.

CONCLUSIONS-

In addition to being common and severely incapacitating, anxiety disorders often co-occur with other serious mental disorders, depression, and substance use disorders. As a result, this group of illnesses is a crucial topic for medical attention. Because of their comparatively modest side effect profile, selective serotonin reuptake inhibitors (SSRIs) have become the major treatment option for many anxiety disorders due to the well-documented adverse effects of benzodiazepines, tricyclic antidepressants, and neuroleptics. Fluvoxamine was the first SSRI to be approved for the treatment of obsessive-compulsive disorder (OCD) and has undergone the most research. Given that several anxiety disorders, especially OCD and social anxiety disorder (SAD), frequently appear in children, it is noteworthy that fluvoxamine has also been extensively studied in pediatric populations.

Double-blind, randomized, controlled trials targeting OCD, SAD, and panic disorder have confirmed fluvoxamine's efficacy. Clomipramine has historically been used as a primary treatment for OCD, however it does not have the cardiotoxicity or usual treatment-limiting anticholinergic and cognitive adverse effects of tricyclic antidepressants. Fluvoxamine also avoids the cognitive impairment and dependence risk associated with benzodiazepines, which are used to treat a variety of anxiety disorders. It is also linked to a low risk of suicidality and is regarded as safe in overdose situations. Fluvoxamine appears to have less sexual side effects and less cognitive impairment than other SSRIs, but it generally has a comparable tolerability profile, chiefly defined by moderate and self-limiting gastrointestinal problems. Fluvoxamine does not cause a severe withdrawal symptoms like paroxetine does. As a result, it can be considered a first-line therapy option for a range of anxiety disorders in both adults and children.

Apart from clinical trials, fluvoxamine's safety and tolerability have been verified by means of comprehensive published post-marketing studies, prescription event monitoring, and targeted studies involving patients who also have other medical conditions, such as polypharmacy and cardiovascular disease.

REFERENCES

1. Wilde MI, Plosker GL, Benfield P. Fluvoxamine: an updated review of its pharmacology and therapeutic use in depressive illness. Drugs. 1993; 46: 895–924.
2. Hyttel J. Comparative pharmacology of selective serotonin reuptake inhibitors (SSRIs) Nord J Psychiatry. 1993;47(Suppl 30):5–12.
3. Hyttel J. Comparative pharmacology of selective serotonin reuptake inhibitors (SSRIs) Nord J Psychiatry. 1993;47(Suppl 30):5–12.
4. Narita N, Hashimoto K, Tomitaka S, et al. Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptor in rat brain. Eur J Pharmacol. 1996; 307:117–19.
5. Njung'e K, Handley SL. Effects of 5-HT uptake inhibitors, agonists and antagonists on burying of harmless objects by mice; a putative test for anxiolytic agents. Br J Pharmacol. 1991; 104:105–12.
6. Olivier B, Bosch L, van-Hest A, et al. Preclinical evidence on the psychotropic profile of fluvoxamine. Pharmacopsychiatry. 1993; 26(Suppl 1):2–9.
7. Woods A, Smith C, Szewczak M, et al. Selective serotonin reuptake inhibitors decrease schedule-induced polydipsia in rats: a potential model for obsessive compulsive disorder. Psychopharmacol. 1993;112:195–8.
8. Overmars H, Scherpenisse PM, Post LC. Fluvoxamine maleate: metabolism in man. Eur J Drug Metab Pharmacokinet. 1983;8:269–80.
9. Piontek CM, Wisner KL, Perel JM, et al. Serum fluvoxamine levels in breastfed infants. J Clin Psychiatry. 2001;62:111–13.
10. van Harten J. Overview of the pharmacokinetics of fluvoxamine. Clin Pharmacokinet. 1995;29(Suppl 1):1–9.
11. Harten J, Duchier J, Devissaguet J-P, et al. Pharmacokinetics of fluvoxamine maleate in patients with liver cirrhosis after single-dose oral administration. Clin Pharmacokinet. 1993;24:177–82.
12. de Vries MH, Raghoebar M, Mathlener IS, et al. Single and multiple oral dose fluvoxamine kinetics in young and elderly subjects. Ther Drug Monit. 1992;14:493–8.
13. DeVane CL. Differential pharmacology of newer antidepressants. J Clin Psychiatry. 1998;59(Suppl 20):85–93.
14. van Harten J, Stevens LA, Raghoebar M, et al. Fluvoxamine does not interact with alcohol or potentiate alcohol-related impairment of cognitive function. Clin Pharmacol Ther. 1992;52:427–35.

15. Milijkovic BR, Pokrajac M, Timotijevic I, et al. The influence of lithium on fluvoxamine therapeutic efficacy and pharmacokinetics in depressed patients on combined fluvoxamine-lithium therapy. Int Clin Psychopharmacol. 1997;12:207–12.

16. Ochs HR, Greenblatt DJ, Verburg-Ochs B, et al. Chronic treatment with fluvoxamine, clovoxamine and placebo: interaction with digoxin and effects on sleep and alertness. J Clin Pharmacol. 1989;29:91–5.

17. Kessler RC, McGonagle KC, Zhao S, et al. Lifetime and 12-month prevalence of DSM-IIIR psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51:8–19.

18. Weiller E, Bisserbe JC, Boyer P, et al. Social phobia in general health care. An unrecognised undertreated disabling disorder. Br J Psychiatry. 1996;168:169–74.

19. Stein MB, Fyer AJ, Davidson JRT, et al. Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. Am J Psychiatry. 1999;156:756–60.

20. Davidson J, Yaryura-Tobias J, Du Pont R, et al. Fluvoxamine-controlled-release formulation for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol. 2004;24:118–25.

21. Westenberg HG, Stein DJ, Yang H, et al. A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol. 2004;24:49–55. MacQueen G, Born L, Steiner M. The selective serotonin reuptake inhibitor sertraline: its profile and use in psychiatric disorders. CNS Drug Rev. 2001;7:1–24.

22. Wagstaff AJ, Cheer SM, Matheson AJ, et al. Paroxetine: an update of its use in psychiatric disorders in adults. Drugs. 2002;62:655–703.

23. Kobak KA, Greist JH, Jefferson JW, et al. Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study. J Clin Psychopharmacol. 2002;22:257–62.